content: <PAGE>
  <TABLE>
  <CAPTION>
  <S>                                                                     <C>
                         SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
   Date of Report (Date of earliest event reported): December 6, 2001 (December 5, 2001)
  
                               COR THERAPEUTICS, INC.
               (Exact name of registrant as specified in its charter)
  
         Delaware                    0-19290                       94-3060271
  (State of jurisdiction)     (Commission File No.)      (IRS Employer Identification No.)
  
                                256 East Grand Avenue
                        South San Francisco, California 94080
                (Address of principal executive offices and zip code)
  
         Registrant's telephone number, including area code: (650) 244-6800
  </TABLE>
  
                                         1.
  
  <PAGE>
  
  Item 5.      Other Events
  
       On December 5, 2001, COR Therapeutics, Inc., a Delaware corporation
  ("COR"), entered into an Agreement and Plan of Merger (the "Merger Agreement")
  among COR, Millennium Pharmaceuticals, Inc., a Delaware corporation
  ("Millennium"), and PGM Corporation, a Delaware corporation and wholly owned
  subsidiary of Millennium. Pursuant to the Merger Agreement, each outstanding
  share of common stock of COR will be converted into the right to receive 0.9873
  shares of common stock of Millennium. Upon consummation of the merger,
  Millennium will issue or reserve for issuance approximately 78,472,843 shares of
  its common stock for conversion of all of the outstanding securities of COR,
  including approximately 16,155,535 shares issuable upon conversion of COR's
  outstanding convertible notes. The consummation of the merger is subject to
  customary closing conditions, including the approval of the stockholders of
  Millennium and the stockholders of COR and the receipt of certain governmental
  approvals.
  
       The merger is intended to constitute a tax-free reorganization for tax
  purposes. Pursuant to the Merger Agreement, Millennium will assume COR's
  outstanding stock option plans, and each outstanding COR stock option will
  become exercisable for shares of the common stock of Millennium. In addition,
  COR's 5.00% Convertible Subordinated Notes due March 1, 2007 and 4.50%
  Convertible Senior Notes due June 15, 2006, aggregating $600 million in
  outstanding principal amount, will become convertible into a number of shares of
  the common stock of Millennium as is equal to the number of shares as would have
  been issuable had the note holders converted the notes in full immediately prior
  to the merger. Upon consummation of the merger, Vaughn M. Kailian, Shaun R.
  Coughlin, Ginger L. Graham and Ernest Mario will each be elected as a member of
  Millennium's board of directors.
  
       In connection with the execution of the Merger Agreement, Millennium
  entered into a Voting Agreement with certain directors and officers of COR who
  have voting control of less than 1% of the outstanding shares of COR common
  stock pursuant to which, among other things, each such director and officer has
  agreed to vote his or her shares of COR common stock in favor of the merger. COR
  also entered into a Voting Agreement with certain directors and officers of
  Millennium who have voting control of approximately 2.1% of the outstanding
  shares of the common stock of Millennium, pursuant to which, among other things,
  each such director and officer has agreed to vote his or her shares of common
  stock of Millennium in favor of the merger.
  
       As of December 5, 2001, Millennium's directors and executive officers held
  approximately 4,812,012 shares of the common stock of Millennium and options to
  purchase approximately 5,555,033 shares of the common stock of Millennium. As of
  December 5, 2001, COR's directors and executive officers held approximately
  512,834 shares of the common stock of the COR and options to purchase
  approximately 2,627,334 shares of the common stock of COR.
  
       The transaction was announced publicly on December 6, 2001. The description
  contained in this Item 5 of the transactions contemplated by the Merger
  Agreement is qualified
  
                                         2.
  
  <PAGE>
  
  in its entirety by reference to the full text of the Merger Agreement, a copy of
  which is attached to this Current Report on Form 8-K as Exhibit 2.1 and is
  incorporated herein by reference.
  
       In connection with the execution of the Merger Agreement, COR amended its
  stockholders' rights agreement to provide, among other things, that no person or
  entity would be considered to be an "acquiring person" thereunder by reason of
  any transaction contemplated by the merger agreement. COR's amendment to its
  rights agreement, dated December 5, 2001, is attached hereto as Exhibit 99.2.
  
  Item 7.      Financial Statements, Pro Forma Financial Information and Exhibits.
  
  (c)          Exhibits
  
  Exhibit 99.1      Agreement and Plan of Merger, dated as of December 5, 2001,
                    among Millennium Pharmaceuticals, Inc., PGM Corporation and
                    COR Therapeutics, Inc.
  
  Exhibit 99.2      Amendment to Rights Agreement, dated December 5, 2001, between
                    COR Therapeutics, Inc. and Mellon Investor Services LLC (as
                    successor to Chemical Trust Company of California)
  
                                         3.
  
  <PAGE>
                                    SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                     COR THERAPEUTICS, INC.
  
  Dated: December 6, 2001            By: /s/ Patrick Broderick
                                         -------------------------------------
                                         Patrick Broderick
                                         Senior Vice President and General Counsel
  
                                         4.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.txt", "description": "FORM 8-K DATED 12/05/2001", "secsgml_size_bytes": 6225}]
metadata_filer: {"company-data": {"conformed-name": "COR THERAPEUTICS INC / DE", "cik": "0000874865", "assigned-sic": "2834", "irs-number": "943060271", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19290", "film-number": "1808218"}, "business-address": {"street1": "256 E GRAND AVE STE 80", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "4152446800"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
   Date of Report (Date of earliest event reported): December 6, 2001 (December 5, 2001)
  
                               COR THERAPEUTICS, INC.
               (Exact name of registrant as specified in its charter)
  
         Delaware                    0-19290                       94-3060271
  (State of jurisdiction)     (Commission File No.)      (IRS Employer Identification No.)
  
                                256 East Grand Avenue
                        South San Francisco, California 94080
                (Address of principal executive offices and zip code)
  
         Registrant's telephone number, including area code: (650) 244-6800
  1.
  Item 5.      Other Events
  
       On December 5, 2001, COR Therapeutics, Inc., a Delaware corporation
  ("COR"), entered into an Agreement and Plan of Merger (the "Merger Agreement")
  among COR, Millennium Pharmaceuticals, Inc., a Delaware corporation
  ("Millennium"), and PGM Corporation, a Delaware corporation and wholly owned
  subsidiary of Millennium. Pursuant to the Merger Agreement, each outstanding
  share of common stock of COR will be converted into the right to receive 0.9873
  shares of common stock of Millennium. Upon consummation of the merger,
  Millennium will issue or reserve for issuance approximately 78,472,843 shares of
  its common stock for conversion of all of the outstanding securities of COR,
  including approximately 16,155,535 shares issuable upon conversion of COR's
  outstanding convertible notes. The consummation of the merger is subject to
  customary closing conditions, including the approval of the stockholders of
  Millennium and the stockholders of COR and the receipt of certain governmental
  approvals.
  
       The merger is intended to constitute a tax-free reorganization for tax
  purposes. Pursuant to the Merger Agreement, Millennium will assume COR's
  outstanding stock option plans, and each outstanding COR stock option will
  become exercisable for shares of the common stock of Millennium. In addition,
  COR's 5.00% Convertible Subordinated Notes due March 1, 2007 and 4.50%
  Convertible Senior Notes due June 15, 2006, aggregating $600 million in
  outstanding principal amount, will become convertible into a number of shares of
  the common stock of Millennium as is equal to the number of shares as would have
  been issuable had the note holders converted the notes in full immediately prior
  to the merger. Upon consummation of the merger, Vaughn M. Kailian, Shaun R.
  Coughlin, Ginger L. Graham and Ernest Mario will each be elected as a member of
  Millennium's board of directors.
  
       In connection with the execution of the Merger Agreement, Millennium
  entered into a Voting Agreement with certain directors and officers of COR who
  have voting control of less than 1% of the outstanding shares of COR common
  stock pursuant to which, among other things, each such director and officer has
  agreed to vote his or her shares of COR common stock in favor of the merger. COR
  also entered into a Voting Agreement with certain directors and officers of
  Millennium who have voting control of approximately 2.1% of the outstanding
  shares of the common stock of Millennium, pursuant to which, among other things,
  each such director and officer has agreed to vote his or her shares of common
  stock of Millennium in favor of the merger.
  
       As of December 5, 2001, Millennium's directors and executive officers held
  approximately 4,812,012 shares of the common stock of Millennium and options to
  purchase approximately 5,555,033 shares of the common stock of Millennium. As of
  December 5, 2001, COR's directors and executive officers held approximately
  512,834 shares of the common stock of the COR and options to purchase
  approximately 2,627,334 shares of the common stock of COR.
  
       The transaction was announced publicly on December 6, 2001. The description
  contained in this Item 5 of the transactions contemplated by the Merger
  Agreement is qualified
  
                                         2.
  in its entirety by reference to the full text of the Merger Agreement, a copy of
  which is attached to this Current Report on Form 8-K as Exhibit 2.1 and is
  incorporated herein by reference.
  
       In connection with the execution of the Merger Agreement, COR amended its
  stockholders' rights agreement to provide, among other things, that no person or
  entity would be considered to be an "acquiring person" thereunder by reason of
  any transaction contemplated by the merger agreement. COR's amendment to its
  rights agreement, dated December 5, 2001, is attached hereto as Exhibit 99.2.
  
  Item 7.      Financial Statements, Pro Forma Financial Information and Exhibits.
  
  (c)          Exhibits
  
  Exhibit 99.1      Agreement and Plan of Merger, dated as of December 5, 2001,
                    among Millennium Pharmaceuticals, Inc., PGM Corporation and
                    COR Therapeutics, Inc.
  
  Exhibit 99.2      Amendment to Rights Agreement, dated December 5, 2001, between
                    COR Therapeutics, Inc. and Mellon Investor Services LLC (as
                    successor to Chemical Trust Company of California)
  
                                         3.
  SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                     COR THERAPEUTICS, INC.
  
  Dated: December 6, 2001            By: /s/ Patrick Broderick
                                         -------------------------------------
                                         Patrick Broderick
                                         Senior Vice President and General Counsel
  
                                         4.